Illinois Municipal Retirement Fund Sells 33,543 Shares of Pfizer Inc. $PFE

Illinois Municipal Retirement Fund lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 4.3% in the third quarter, HoldingsChannel.com reports. The fund owned 750,341 shares of the biopharmaceutical company’s stock after selling 33,543 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Pfizer were worth $21,400,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its stake in shares of Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after buying an additional 745,213 shares during the last quarter. Handelsbanken Fonder AB raised its position in Pfizer by 10.4% during the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after acquiring an additional 232,528 shares in the last quarter. Leuthold Group LLC acquired a new position in Pfizer in the second quarter valued at approximately $4,887,000. Park National Corp OH lifted its holdings in Pfizer by 332.1% in the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after acquiring an additional 186,053 shares during the period. Finally, 111 Capital acquired a new position in Pfizer in the second quarter valued at approximately $3,706,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of analyst reports. Freedom Broker raised their price objective on shares of Pfizer from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. JPMorgan Chase & Co. boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Royal Bank Of Canada boosted their target price on shares of Pfizer from $25.00 to $28.00 and gave the company a “sector perform” rating in a research note on Wednesday, November 4th. Scotiabank increased their price target on shares of Pfizer from $33.00 to $35.00 and gave the stock a “sector outperform” rating in a report on Wednesday, November 4th. Finally, UBS Group raised their price target on shares of Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a research report on Wednesday, November 4th. Six research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus price target of $30.39.

Pfizer Price Performance

Shares of Pfizer stock opened at $29.32 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.42 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $23.62 and a twelve month high of $31.44. The business has a 50-day moving average price of $28.79 and a 200 day moving average price of $26.94. The firm has a market cap of $167.13 billion, a PE ratio of 9.58, a P/E/G ratio of 1.92 and a beta of 0.31.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. The company had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. Pfizer’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.87 EPS. Sell-side analysts predict that Pfizer Inc. will post 3.04 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.9%. Pfizer’s payout ratio is 245.71%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported positive Phase 3 MagnetisMM-32 results for ELREXFIO in patients with relapsed or refractory multiple myeloma, supporting the drug’s potential use after prior treatments. The company also partnered with Edison Scientific to apply AI tools across its research pipeline, which could support drug discovery. Pfizer Phase 3 and AI research article
• Positive Sentiment: Pfizer raised its 2026 revenue outlook by $1.5 billion at the midpoint, to $62 billion–$64 billion. The report attributes the improved outlook to business momentum and puts renewed attention on the company’s growth prospects. Pfizer higher 2026 outlook article
• Positive Sentiment: Commentary points to growth from recently launched and acquired products, while Pfizer’s Metsera acquisition gives it potential exposure to the GLP-1 market. However, its obesity treatment may not launch until 2028, making this a longer-term opportunity rather than a near-term revenue driver. Pfizer product growth article Pfizer GLP-1 opportunity article
• Neutral Sentiment: Cecile Guegan has become Pfizer’s permanent CFO, the company’s first woman in the role. The appointment comes as Pfizer manages major pipeline investments, including obesity-drug development; the report does not indicate an immediate financial impact. Pfizer CFO appointment article
• Neutral Sentiment: Arbutus Biopharma and Genevant expanded patent lawsuits against Pfizer and BioNTech in Japan and Canada over lipid nanoparticle technology used in COVID-19 vaccines, seeking damages and injunctions. These are ongoing claims, not a court decision, but they preserve potential legal and financial uncertainty. Arbutus litigation update

Pfizer Company Profile

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.